Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Aldeyra nets $27mm via FOPO

Executive Summary

Aldeyra Therapeutics Inc. (developing therapies for diseases related to endogenous aldehyde toxicity) netted $27mm through the follow-on offering of 3.97mm common shares (including full exercise of the overallotment) priced at $7.25. The company will use some of the proceeds for ongoing development of candidates including its lead program ADX102, which is being developed in different formulations. An ophthalmic solution is in Phase III for noninfectious anterior uveitis and Phase II for allergic conjunctivitis and dry eye syndrome. Topical ADX102 is in Phase III for Sjögren-Larsson syndrome and oral ADX102 is in earlier-stage studies for Sjögren-Larsson syndrome and SSADH deficiency.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies